← Back to Clinical Trials
Recruiting NCT07817199

NCT07817199 Time Comparison of Interventions on Bowel Programs in Spinal Cord Injury

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07817199
Status Recruiting
Phase —
Sponsor Casa Colina Hospital and Centers for Healthcare
Condition Spinal Cord Injury
Study Type INTERVENTIONAL
Enrollment 30 participants
Start Date 2026-10-01
Primary Completion 2027-07-01

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
SuppositoryEnemeezPeristeen

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 30 participants in total. It began in 2026-10-01 with a primary completion date of 2027-07-01.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The goal of the study is to find out which of three different options (a suppository, a mini enema, or a transanal irrigation device) takes the least amount of time for completing bowel program amongst those who have spinal cord injuries with a neurogenic bowel. The main questions this study aims to answer are: * Does one of these tools meaningfully reduce the amount of time people with spinal cord injury need to complete their bowel programs? * Does one of these tools meaningfully reduce the number of times someone might experience incontinence or constipation? * Are participants satisfied in using these devices, and would they prefer to use the same tool at home? Researchers will compare the answers to these questions between the three different tools to improve quality of life for patients while improving the efficiency of the care provided. Participants in this study will: * Be enrolled in one of these options depending on when they are admitted to Casa Colina Hospital * Will receive the same tool for their bowel program for the majority or entirety of their stay * Will have a tracking sheet placed in their rooms for nursing to record when bowel program started and when it was completed * Will receive questionnaires when they enroll and when they finish the study on their experience with the tool and how likely they would be to use it at home

Eligibility Criteria

Inclusion Criteria: * admission to acute rehab inpatient unit * diagnosis of spinal cord injury * reflexive type neurogenic bowel requiring bowel program with suppository and digital stimulation Exclusion Criteria: * anal or rectal stenosis * active inflammatory bowel disease * acute diverticulitis * colorectal cancer * ischemic colitis * rectal surgery within the last 3 months * endoscopic polypectomy within the last 4 weeks * areflexic bowel * severe autonomic dysreflexia

Contact & Investigator

Central Contact

Megan Narintarangkool

✉ mnarintarangkool@casacolina.org

📞 (909)596-7733

Principal Investigator

Emily Rosario, PhD

STUDY DIRECTOR

Casa Colina Hospital and Centers for Healthcare

Frequently Asked Questions

Who can join the NCT07817199 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Spinal Cord Injury. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07817199 currently recruiting?

Yes, NCT07817199 is actively recruiting participants. Contact the research team at mnarintarangkool@casacolina.org for enrollment information.

Where is the NCT07817199 trial being conducted?

This trial is being conducted at Pomona, United States.

Who is sponsoring the NCT07817199 clinical trial?

NCT07817199 is sponsored by Casa Colina Hospital and Centers for Healthcare. The principal investigator is Emily Rosario, PhD at Casa Colina Hospital and Centers for Healthcare. The trial plans to enroll 30 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: November 2026  ·  Data Methodology